In previous studies, RTP4 was shown to regulates prostate cancer via methylation and is regarded as a precise target, whose expression levels can be used to independently predict the prognosis of HER2(+) breast cancer (Laurin et al., 2013; Xu et al., 2019). Here, ERBB2 is linked to prostate carcinoma.